Pyxis Oncology reports Q3 2023 net loss $23.0M; cuts headcount 40% to extend cash runway into early 2026

Pyxis Oncology, Inc.

2023-Q3 EPS reported -$1.52

Net loss of $23.0M ($0.56 per share) for Q3 2023, vs $27.7M ($0.85 per share) in Q3 2022.
Cash, restricted cash, and short-term investments total $134.4M as of Sept 30, 2023.
Announces 40% headcount reduction and pausing early-stage research to extend cash runway into early 2026.
PYX-201 Phase 1 fifth dose cohort at 3.6 mg/kg; preliminary data expected 1H 2024. PYX-106 refocused on NSCLC; data expected 2H 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pyxis Oncology, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 7, 2023, Pyxis Oncology, Inc., or the Company, issued a press release announcing its financial results for the quarter ended September 30, 2023

View on SEC.gov

Browse all earnings releases →

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-060352

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.